Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: Kezar Life Sciences(KZR) the EBIT is -6.753 M (+61.69%);the EPS is -0.784 (+65.41%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.01B61.69%
----
----
EPS
-0.783865.41%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf